In the Claims:

Please amend the claims as follows:

Please cancel claims 15-19, without prejudice.

Please amend claims 2, 4-7, 9-13, and 20-22 in accordance with 37 C.F.R. §1.121(c) to read as follows, including all of the changes shown in the attached Marked Up Version of the Claims in which additions are shown by underlining and deletions are shown by bracketing:

A2

2. (Amended) A composition as claimed in claim 1 for use in medicine.

4. (Amended) A composition as claimed in claim 3, wherein the solvent is propylene glycol or glycofurol (tetraglycol).

5. (Amended) A composition as claimed in claim 1, wherein the pharmaceutical excipient is a material which is able to complex with the fexofenadine or pharmaceutically acceptable salt thereof.

A3

6. (Amended) A composition as claimed in claim 1, wherein the pharmaceutical excipient is a cyclodextrin.

7. (Amended) A composition as claimed in claim 6, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

9. (Amended) A composition as claimed in claim 1, which further comprises a gelling agent or bioadhesive material.

A4

10. (Amended) A composition as claimed in claim 9, wherein the gelling agent or bioadhesive material is a polysaccharide.

11. (Amended) A composition as claimed in claim 10, wherein the gelling agent

or bioadhesive material is selected from the group consisting of pectin, alginate, starch, gellan and chitosan.

12. (Amended) A composition as claimed in claim 9, wherein the gelling agent is a block co-polymer.

13. (Amended) A composition as claimed in claim 12, wherein the block co-polymer is a poloxamer.

20. (Amended) A method of treating a patient in need of treatment with fexofenadine or a pharmaceutically acceptable salt thereof which comprises administering an effective amount of a composition according to claim 1 to a patient in need of such treatment.

21. (Amended) A method of treating rhinitis which comprises administering an effective amount of a composition according to claim 1, to a patient in need of such treatment.

22. (Amended) A method of treating a patient with a controlled release dose of fexofenadine or a pharmaceutically acceptable salt thereof which comprises administering an effective amount of a composition according to claim 9, to a patient in need of such treatment.

REMARKS

Claims 1-14 and 20-22 are pending in the application.

Claims 2, 4-7, 9-13, and 20-22 have been amended to make minor cosmetic corrections in response to the Examiner's observations on page 5 of Paper No. 5.

The specification has been amended in order to update the "Cross-Reference to Related Applications" section.

In accordance with 37 C.F.R. § 1.121, a marked-up version of the specification and a marked-up version of the claims, showing the changes made, are provided herewith. Claims 15-19 have been cancelled without prejudice.

The Examiner has indicated that claims 5-8 and 21 contain allowable subject matter and would be allowable if each was rewritten in independent form to include all of the